Abstract
Peroxisome-proliferator-activated receptor-γ (PPAR-γ) agonists (known as thiazolidinediones; TDZs) activate nuclear receptors that regulate gene expression; they were developed as insulin-sensitizing drugs to treat type 2 diabetes mellitus. Although the prototypic TZD troglitazone was withdrawn from the market due to hepatic toxicity, rosiglitazone and pioglitazone are mainstays in managing type 2 diabetes mellitus. TZDs exert their hypoglycemic effect by reducing insulin resistance, hence improving insulin sensitivity. However, TZDs also exhibit a broad range of cardiovascular actions, with the clinical consequence of reduction in blood pressure (BP), observed in animal models and human diabetic subjects. The magnitude of reduction appears to be about 4 to 5 mm Hg in systolic and 2 to 4 mm Hg in diastolic BP—sufficient to significantly reduce subsequent cardiovascular event rates. But these BP-reducing properties, which are not present with metformin or sulfonylureas, are particularly important when viewed in conjunction with hypoglycemic effects. A significant proportion of patients with type 2 diabetes mellitus and BP mildly above target range might be successfully treated for both processes with a single drug.
Similar content being viewed by others
References and Recommended Reading
Gurnell M, Savage DB, Chatterjee VK, O’Rahilly S: The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003, 88:2412–2421.
Sarafidis PA, Nilsson PM: The effects of thiazolidinediones on blood pressure levels: a systematic review. Blood Pressure 2006, 15:135–150.
Sarafidis PA, Lasaridis AN: Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006, 19:646–653.
Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.
Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866–1870.
Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409–435.
Berger JP, Petro AE, Macnaul KL, et al.: Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003, 17:662–676.
Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001, 70:341–367.
Dubois M, Pattou F, Kerr-Conte J, et al.: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000, 43:1165–1169.
Lebovitz HE, Banerji MA: Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001, 56:265–294.
Haffner SM: Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl 1997, 15:S25–30.
Natali A, Quinones Galvan A, Santoro D, et al.: Relationship between insulin release, antinatriureis and hypokalaemia after glucose ingestion in normal and hypertensive man. Clin Sci (Lond) 1993, 85:317–335.
Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skeletal muscle blood flow inpatients with NIDDM. Diabetes 1992, 41:1076–1083.
Barbagallo M, Gupta RK, Bardicef O, et al.: Mieredionic effects of insulin in hypertension role of basalion levels in determining cellular responsiveness. J Clin Endocrinol Metab 1997, 82:1761–1765.
Trovati M, Anfossi G: Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002, 16:35–43.
Picard F, Auwerx J: PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002, 22:167–197.
Miyazaki Y, Mahankali A, Matsuda M, et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Exdocrinol Metab 2002, 87:2784–2791.
Okuno A, Tamemoto H, Tobe K, et al.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998, 101:1354–1361.
Knock A, Mishra SK, Aaronson PI: Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 1999, 368:103–109.
Kawasaki J, Hirano K, Nishimura J, et al.: Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 1998, 98:2446–2452.
Fujioka Y, Masai M, Tsuboi S, et al.: Troglitazone reduces activity of the Na+/H+ exchanger in fructose-fed borderline hypertensive rats. Hypertens Res 2003, 26:111–116.
Buchanan TA, Meehan WP, Jeng Y, et al.: Bloodpressure lowering by pioglitazone: evidence for a directvascular effect. J Clin Invest 1995, 96:354–360.
de Dios ST, Hannan KM, Dilley RJ, et al.: Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Complications 2001, 15:120–127.
Qayyum R, Schulman P: Cardiovascular effects of the thiazolidinediones. Diabetes Metab Res Rev 2006, 22:88–97.
Saku K, Zhang B, Ohta T, Arakawa K: Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am J Hypertens 1997, 10:1027–1033.
Czoski-Murray C, Warren E, Chilcott J, et al.: Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004, 8:1–91.
Bennett SM, Agrawal A, Elasha H, et al.: Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabetes Med 2004, 21:415–422.
Sung BH, Izzo JL Jr, Dandona P, Wilson MF: Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999, 34:83–88.
Negro R, Mangieri T, Dazzi D, et al.: Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005, 70:20–25.
Negro R, Dazzi D, Hassan H, Pezzarossa A: Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol 2004, 29:11–17.
Ohigara T, Rakugi H, Ikegami H, et al.: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995, 8:316–320.
Derosa G, Cicero AF, Gaddi AV, et al.: Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther 2005, 27:1383–1391.
Sarafidis PA, Lasaridis AN, Nilsson PM, et al.: The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005, 18(2 Pt 1):227–234.
Raji A, Seely EW, Bekins SA, et al.: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003, 26:172–178.
Yosefy C, Magen E, Kiselevich A, et al.: Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004, 44:215–222.
St John Sutton M, Rendell M, Dandona P, et al.: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002, 25:2058–2064.
Qayyum R, Adomaityte J: A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 2006, 8:19–28.
Dormandy A, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) a randomised controlled trial. Lancet 2005, 366:1279–1289.
The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-rist patients. N Engl J Med 2000, 342:145–153.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators—Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105.
DREAM Trial Investigators—Bosch J, Yusuf S, Gerstein HC, et al.: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006, 355:1551–1562.
Cook NR, Cohen J, Hebert PR, et al.: Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995, 155:701–709.
Lewington S, Clarke R, Qizilbash N, et al., Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.
Giles TD, Berk BC, Black HR, et al., on behalf of the Writing Group of the American Society of Hypertension (ASH): Expanding the definition and classification of hypertension. J Clin Hypertens 2005, 7:505–512.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giles, T.D., Sander, G.E. Effects of thiazolidinediones on blood pressure. Current Science Inc 9, 332–337 (2007). https://doi.org/10.1007/s11906-007-0060-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-007-0060-0